Postoperative hyponatremia is relatively common among postoperative complications that occur in patients who underwent transsphenoidal surgery (TSS) for pituitary adenomas, with incidence varying from 1.8% to 35% [1-6]. Common clinical presentations include headaches, nausea and vomiting, but more severe symptoms like seizures, mental change can develop if left untreated. It is known that significant postoperative hyponatremia usually develops after the latter part of first postoperative week, however, its pathophysiology has been under debate [5,7-9]. Hormonal imbalance caused by disruption of the normal pituitary gland during surgery is thought to be the mechanism behind it, but the exact mechanism or risk factors of postoperative hyponatremia is still unclear despite several previous studies [1,3,4,6,10-13]. As the consequences of untreated hyponatremia are often fatal, this study aims to ascer-
tain risk factors associated with postoperative hyponatremia in patients who underwent TSS for their pituitary adenomas.

MATERIALS AND METHODS

Patient population
Total 1,343 patients with pituitary adenomas operated with TSS in our institution were included in this study. Patients' medical record and imaging studies were retrospectively reviewed. This study was conducted in accordance with the Declaration of Helsinki and approved by Institutional Review Board in our institute (4-2018-0039), waving the patient's written consent as a retrospective study. Delayed hyponatremia was defined as sodium level less than 135 mmol/L that occurred on or after postoperative day 3. We identified 93 patients who presented with rapid drop of their sodium level or significant clinically relevant symptoms, and thus required administration of hypertonic saline (3% NaCl). These 93 patients were defined as hyponatremia group and their clinical features were compared with those of control group.

Patient evaluation
All patients were evaluated preoperatively with dynamic sellar MRI using either 1.5-Tesla system (Signa, General Electric, Minneapolis, MN, USA) or 3.0-Tesla system (Achieva, Philips, Best, The Netherlands). Tumor size was determined as a maximum diameter of the tumor on a coronal view of preoperative MRI. With the preoperative MRI all the patients were classified into modified Hardy's classification of pituitary adenoma [14-16]. Immediate postoperative 3-Tesla MRI was performed 48 hours after the surgery to determine the radicality of tumor removal. Specific methods of endocrinological assessment were fully described in our previous report [13]. Combined pituitary function test (CPFT) was performed to evaluate anterior pituitary function before surgery, 6–12 months after surgery and every 2 years thereafter.

Surgical procedure
All tumors were approached by conventional microscopic or endoscopic transsphenoidal approach. After dural opening, identification of normal anatomy and evaluation of tumor and the surrounding pseudocapsule was done. If the tumor was hard or surrounded by a thick pseudocapsule, dissection was performed along the outer margin of the pseudocapsule. If the tumor was fragile and soft enough, it was removed in a piecemeal fashion. Pseudocapsule was removed in all possible circumstances to prevent recurrence. Hormonal type of pituitary adenoma was confirmed with microscopic examination of specimen with immunohistochemistry of relevant pituitary hormones by a proficient pathologist.

Statistical analysis
Student's t-test was performed to evaluate the difference of average age and tumor size between the hyponatremia group and control. Chi-squared test was performed to evaluate the difference of distribution regarding sex, Hardy classification, hormonal type, preoperative hypopituitarism, tumor removal radicality, tumor removal fashion and hormonal outcome. In all statistical analyses, p-value of <0.05 was considered significant. Statistical analyses were performed using SPSS statistical software (version 15.0; SPSS Inc., Chicago, IL, USA).

RESULTS
Out of total 1,343 pituitary adenoma patients, we identified 93 patients (6.9%) with postoperative hyponatremia that required hypertonic saline infusion. Our routine daily laboratory evaluation includes water intake/output, serum electrolytes (sodium, potassium, chloride), urine specific gravity. Once hyponatremia was detected, 3% NaCl infusion was started immediately when the sodium level was below 130 mmol/L or patient showed significant relevant symptoms. Four hours after initiation of hypertonic saline, serum electrolyte levels were followed up and infusion rate was adjusted, which were repeated until we stabilized hyponatremia. For correction rate of hyponatremia, we stuck to the consensus guidelines [17,18]. The initiation of hypertonic saline infusion, which can be considered as onset of hyponatremia, was 7.8 days after surgery (range: postoperative day 3–13) (Fig. 1). Initial mean serum sodium level right before starting hypertonic saline infusion was 124.3±4.8 mmol/L, ranging from 111 to 132 mmol/L. Patients required average 2.7 days (range: 1–9) of hypertonic saline infusion before resolution of symptoms and sustained recovery of serum sodium level.

Preoperative characteristics
Preoperative characteristics of 93 patients with postoperative hyponatremia are summarized in Table 1. The group included 21 males and 72 females with a mean age of 44.7 (range: 19–75) at the time of surgery. The proportion of female patients were significantly higher in the hyponatremia group compared to control (77.4% vs. 61.4%, p=0.02). The mean preoperative size of tumor was 19.7 mm (range: 5–55). We witnessed no significant difference in age (44.7 ± 43.1, p=0.245) and tumor size (19.7 vs. 19.3, p=0.692). Patients were classified into modified Hardy’s classification, resulting in 31 patients (33.3%) of type I, 15 patients (16.1%) of type II, 31 patients (33.3%) of type III and 16 patients (17.2%) of type IV. Regarding hormonal subtypes, nonfunctioning adenoma was the most common, numbering up to 41 patients (44.1%), followed by growth hormone-secreting (33 patients, 35.5%), prolactin-secreting (11 patients,
Hyponatremia after Transsphenoidal Surgery

Hyponatremia after Transsphenoidal Surgery

11.8%) and adrenocorticotropic-secreting subtype (8 patients, 8.6%). There was no significant difference of distribution regarding modified Hardy's classification, hormonal subtypes of adenomas. Among 1,299 patients who underwent preoperative CPFT, total 917 patients presented with preoperative hypopituitarism in at least one of their pituitary hormone axes. The incidence of preoperative hypopituitarism was lower in a hyponatremia group than in a control group (58.5% vs. 71.5%, p=0.007). However, the incidence of adrenocorticotropic hormone (ACTH) axis hypofunction was similar in both groups.

Postoperative outcomes

Postoperative outcomes are summarized in Table 2. Total resection was achieved in 83 patients (89.2%) of hyponatremia group. Tumors were removed in piecemeal fashion in 55 patients (59.1%) and in capsulectomy fashion in 38 patients (40.9%). There was no significant difference in total resection rate (89.2% vs. 87.8%, p=0.712) or capsulectomy rate (59.1% vs. 64.2%, p=0.328) between the two groups.

44 patients from hyponatremia group and 582 patients from control group (49.4% vs. 48.0%, p=0.796) showed postoperative hypopituitarism in at least one axis of anterior pituitary function. Incidence of pituitary function deterioration after surgery was evaluated with direct comparison of preoperative and postoperative CPFT, and no difference was found between the two groups (10.6% vs. 6.9%, p=0.203). On the contrary, decreased pituitary function in ACTH axis showed strong association with the presence of postoperative hyponatremia (33.7% vs. 23.4%, p=0.029).

DISCUSSION

Patients with hyponatremia present a variety of symptoms from simple headaches, muscle cramps to more severe symptoms like seizures, mental change, respiratory arrest [19]. Severe symptomatic hyponatremia should be managed immediately as delayed treatment can lead to fatal results. Although hyponatremia is a common postoperative complication of TSS, little is known about its time course and risk factors. The exact mechanism behind postoperative hyponatremia is still unknown; theories suggest excessive antidiuretic hormone (ADH) secretion after surgery induced by vagal stimuli (headache, stress, nausea) or immediate release of ADH into vascular space due to surgical exploration as possible mechanisms. Previous studies suggested old age [13], female sex [6], Cushing's disease [10,20], tumor size [11], presence of transient diabetes insipidus as risk factors of postoperative hyponatremia. It is also reported that significant hyponatremia does not occur until the latter part of 1st postoperative week to early 2nd week [5,7-9].

This study retrospectively reviewed data of 1,343 pituitary adenoma patients, of which 93 patients (6.9%) presented with postoperative hyponatremia. The incidence, onset time, and duration of postoperative hyponatremia presented in this study are consistent with previous reports. Various preoperative and postoperative characteristics were analyzed to identify any possible risk factor of hyponatremia. Although old age is a frequently reported risk factor for postoperative hyponatremia, there was no significant difference of average age between the hyponatremia group and the control group in this study. There was significant sex predilection towards female in hyponatremia group compared to control, which was also witnessed by other group [6]. Hormonal type of tumor was not related to...
postoperative hyponatremia. Factors related to higher risk of normal gland violation, such as bigger tumor size or suprasellar extension, was not associated with postoperative hyponatremia. As hyponatremia frequently associates with hypocortisolism [21], we speculated that the incidence of ACTH dysfunction would be higher in a hyponatremia group than in a control group, we failed to demonstrate a statistically significant difference in the incidence of preoperative ACTH dysfunction between two groups. It was an interesting finding that the incidence of hypopituitarism was lower in a hyponatremia group, which may suggest this complication may more frequently associates with patients with relatively well preserved pituitary functional capacity.

There was no difference in total removal rate or capsulectomy rate between the hyponatremia group and the control group. Postoperative hypopituitarism was not associated with postoperative hyponatremia, but postoperative ACTH dysfunction was strongly related to hyponatremia suggesting ACTH dysfunction may be the leading cause of hyponatremia.

Mechanism of postoperative hyponatremia in pituitary adenoma patients is still unclear. Some previous studies suggested that increased level of ADH after surgery may be a possible cause of postoperative hyponatremia [7,22,23]. Unregulated ADH release from surgically manipulated posterior pituitary gland occurs few days after surgery, resulting in fluid retention and natriuresis [10]. This theory is in good agreement with the delayed onset of hyponatremia [7,23]. On the contrary, other studies have also reported cases of hyponatremia in the settings of normal or low level of ADH [9,24-26]. In this case, hyponatremia is explained by actions of atrial natriuretic hormones and brain natriuretic hormone resulting in excessive natriuresis rather than fluid retention, also known as cerebral salt wasting syndrome. As aforementioned, another possible mechanism for delayed hyponatremia is secondary adrenocortical insufficiency [9,27]. Although the present study showed no correlation between hormonal type of pituitary adenoma and postoperative hyponatremia, some previous studies have reported higher risks of hyponatremia after TSS in Cushing patients compared to prolactinoma by 3 folds, or non-functioning adenomas by 2.8 folds [24]. This study showed that postoperative adrenal insufficiency can be a risk factor for delayed hyponatremia. It should be further investigated whether adequate cortisol replacement could prevent development of postoperative hyponatremia.

This study defined hyponatremia group as patients with postoperative hyponatremia. Factors related to higher risk of normal gland violation, such as bigger tumor size or suprasellar extension, was not associated with postoperative hyponatremia.

**Table 1. Preoperative characteristics of patients**

|                         | Patients with postoperative hyponatremia (%) | Patients without postoperative hyponatremia (%) | p-value |
|-------------------------|---------------------------------------------|-----------------------------------------------|---------|
| Number of patients      | 93                                          | 1,250                                        |         |
| Age (year)              | 44.7                                        | 43.1                                         | 0.692   |
| Sex (male:female)       | 21:72                                       | 482:768                                     | 0.002†  |
| Hardy classification (%)|                                             |                                              | 0.199   |
| I                       | 31 (33.3)                                   | 298 (23.8)                                  |         |
| II                      | 15 (16.1)                                   | 234 (18.7)                                  |         |
| III                     | 31 (33.3)                                   | 437 (35.0)                                  |         |
| IV                      | 16 (17.2)                                   | 281 (22.5)                                  |         |
| Tumor size (mm)         | 19.71±11.54                                 | 19.29±9.96                                  | 0.245   |
| Hormonal type (%)       |                                             |                                              | 0.490   |
| NFT                     | 41 (44.1)                                   | 592 (47.4)                                  |         |
| GH                      | 33 (35.5)                                   | 388 (31.0)                                  |         |
| PRL                     | 11 (11.8)                                   | 150 (12.0)                                  |         |
| ACTH                    | 8 (8.6)                                     | 88 (7.0)                                    |         |
| TSH                     | 0 (0.0)                                     | 32 (2.6)                                    |         |
| Hormonal activity       |                                             |                                              |         |
| Preoperative hypopituitarism/total patients evaluated by CPFT* | 55/94 (58.5) | 862/1,205 (71.5) | 0.007† |
| Subnormal response in ACTH axis/total patients evaluated by CPFT* | 22/90 (24.4) | 325/1,209 (26.9) | 0.614 |

*Patients without preoperative CPFT were excluded, †p<0.05. ACTH, adrenocorticotropin hormone; CPFT, combined pituitary function test; GH, growth hormone; NFT, non-functioning tumor; PRL, prolactin; TSH, thyroid stimulating hormone

**Table 2. Postoperative outcomes of the patients**

|                         | Patients with postoperative hyponatremia (%) | Patients without postoperative hyponatremia (%) | p-value |
|-------------------------|---------------------------------------------|-----------------------------------------------|---------|
| Total resection number/total number of the patients* | 83/93 (89.2) | 1,096/1,246 (87.8) | 0.712   |
| Tumor removal fashion (piecemeal:capsulectomy)* | 55:38 | 796:444 | 0.328   |
| Postoperative hypopituitarism/total patients evaluated by CPFT* | 44/89 (49.4) | 582/1,212 (48.0) | 0.796   |
| Subnormal response in ACTH axis/total patients evaluated by CPFT* | 30/89 (33.7) | 284/1,212 (23.4) | 0.029‡  |
| Worsened pituitary function/total patients evaluated by CPFT* | 9/85 (10.6) | 80/1,159 (6.9) | 0.203   |

*Number of patients after excluding any patients with missing data, †Number of patients who were evaluated by combined pituitary function test for their pituitary function, ‡p<0.05. ACTH, adrenocorticotropin hormone; CPFT, combined pituitary function test
operative hyponatremia with symptoms severe enough to need hypertonic saline infusion. Overall incidence of hyponatremia might have been underrated compared to previous studies. We were not able to provide a reasonable explanation for the female predilection reported in hyponatremia group. Although some of the previous studies have reported the same, none had success in providing a meaningful discussion. This study did not include any analysis regarding the mechanism of hyponatremia such as serum ADH level or urine sodium level. The hyponatremia group we set might be heterogeneous, including different types of hyponatremia. The primary endpoint of this study was to seek for any clinical factor relevant to postoperative hyponatremia. Further study regarding the mechanism behind postoperative hyponatremia needs to be done.

In conclusion, postoperative hyponatremia is a common complication after TSS. Recognition of its risk factors is essential since delayed detection or treatment can lead to critical results. While tumor size, modified Hardy classification and tumor removal radicality were not associated with delayed hyponatremia, we demonstrated delayed postoperative hyponatremia was more prevalent in female and patients with perioperative pituitary dysfunction, rendering them as possible risk factors.

Conflicts of Interest

The authors have no potential conflicts of interest.

Acknowledgments

The authors thank Juyoon Park, RN, MPH, OCN, Min Kyeong Jang, PhD, RN, KOAPN, Sung Ja Kang, RN, Sujin Ryu, RN, Young Hwa Yim, MSN, RN, KCAPN, Yong Jun Jang, RN for their tremendous effort in performing the endocrinological tests and data acquisition for such a long follow-up duration. This study was supported by a faculty research grant of Yonsei University College of Medicine (6-2020-0224).

ORCID iDs

Eui Hyun Kim https://orcid.org/0000-0002-2523-7122
Yun Gi Hong https://orcid.org/0000-0001-6208-3233

REFERENCES

1. Olson BR, Gumowski J, Rubino D, Oldfield EH. Pathophysiology of hyponatremia after transsphenoidal pituitary surgery. J Neurosurg 1997;87:499-507.
2. Olson BR, Rubino D, Gumowski J, Oldfield EH. Isolated hyponatremia after transsphenoidal pituitary surgery. J Clin Endocrinol Metab 1995;80:85-91.
3. Sane T, Rantakari K, Poranen A, Tähtelä R, Välimäki M, Pelkonen R. Hyponatremia after transsphenoidal surgery for pituitary tumors. J Clin Endocrinol Metab 1994;79:1395-8.
4. Sata A, Hizuka N, Kawamata T, Hori T, Takanawa K. Hyponatremia after transsphenoidal surgery for hypotalamo-pituitary tumors. Neuroendocrinology 2006;83:117-22.
5. Taylor SL, Tyrell JB, Wilson CB. Delayed onset of hyponatremia after transsphenoidal surgery for pituitary adenomas. Neurosurgery 1995;37:649-53; discussion 653-4.
6. Zada G, Liu CY, Fishback D, Singer PA, Weiss MH. Recognition and management of delayed hyponatremia following transsphenoidal pituitary surgery. J Neurosurg 2007;106:66-71.
7. Cusick JF, Hagen TC, Findling JW. Inappropriate secretion of antidiuretic hormone after transsphenoidal surgery for pituitary tumors. N Engl J Med 1984;311:36-8.
8. Murté GE, Lamballe P, Welch AR. Early inappropriate secretion of antidiuretic hormone after trans-sphenoidal pituitary adenectomy. J Laryngol Otol 1990;104:894-5.
9. Whitaker SJ, Meanock CJ, Turner GF, et al. Fluid balance and secretion of antidiuretic hormone following transsphenoidal pituitary surgery. A preliminary series. J Neurosurg 1985;63:404-12.
10. Hensen J, Henig A, Falbush R, Meyer M, Boehmert M, Buchfelder M. Prevalence, predictors and patterns of postoperative polyuria and hyponatraemia in the immediate course after transsphenoidal surgery for pituitary adenomas. Clin Endocrinol (Oxf) 1999;50:431-9.
11. Kelly DF, Laws ER Jr, Fossett D. Delayed hyponatremia after transsphenoidal surgery for pituitary adenoma. Report of nine cases. J Neurosurg 1995;83:363-7.
12. Kinoshita Y, Tominaga A, Arita K, et al. Post-operative hyponatremia in patients with pituitary adenoma: post-operative management with a uniform treatment protocol. Endocr J 2011;58:373-9.
13. Lee JI, Cho WH, Choi BK, Cha SH, Song GS, Choi CH. Delayed hyponatremia following transsphenoidal surgery for pituitary adenoma. Neuror Med Chir (Tokyo) 2008;48:489-92; discussion 492-4.
14. Kim EH, Oh MC, Kim SH. Application of low-field intraoperative magnetic resonance imaging in transsphenoidal surgery for pituitary adenomas: technical points to improve the visibility of the tumor resection margin. Acta Neurochir (Wien) 2013;155:885-93.
15. Kim J, Yoon SJ, Moon JH, et al. Clinical significance of radical surgery in the treatment of silent corticotroph adenoma. J Korean Neurosurg Soc 2019;62:114-22.
16. Oh MC, Kim EH, Kim SH. Coexistence of intracranial aneurysm in 800 patients with surgically confirmed pituitary adenoma. J Neurosurg 2012;116:942-7.
17. Spasovski G, Vanholder R, Alloio B, et al. Clinical practice guideline on diagnosis and treatment of hyponatraemia. Nephrol Dial Transplant 2014;29 Suppl 2:i1-39.
18. Verbalis JG, Goldsmith SR, Greenberg A, et al. Diagnosis, evaluation, and treatment of hyponatremia: expert panel recommendations. Am J Med 2013;126(10 Suppl 1):S1-42.
19. Adrogue HJ, Madias NE. Hyponatremia. N Engl J Med 2000;342:1581-9.
20. Adams JR, Blevins LS Jr, Allen GS, Verity DK, Devin JK. Disorders of water metabolism following transsphenoidal pituitary surgery: a single institution’s experience. Pituitary 2006;9:93-9.
21. Raff H. Glucocorticoid inhibition of neurohypophyseal vasopressin secretion. Am J Physiol 1987;252(4 Pt 2):R635-44.
22. Lester MC, Nelson PB. Neurological aspects of vasopressin release and the syndrome of inappropriate secretion of antidiuretic hormone. Neurosurgery 1981;8:735-40.
23. Uhmann MC, Hoffman GE, Nelson PB, Robinson AG. Transient hyponatremia after damage to the neurohypophyseal tracts. Neuroendocrinology 1992;56:803-11.
24. Diringer M, Ladenson PW, Borel C, Hart GK, Kirsch JR, Hanley DE. Sodium and water regulation in a patient with cerebral salt wasting. Arch Neurol 1989;46:928-30.
25. Kern PA, Robbins RJ, Bichet D, Beul T, Verbalis JG. Syndrome of inappropriate antidiuresis in the absence of arginine vasopressin. J Clin Endocrinol Metab 1986;62:148-52.
26. Wijdicks EF, Ropper AH, Hunnicutt EJ, Richardson GS, Nathanson JA. Atrial natriuretic factor and salt wasting after aneurysmal subarachnoid hemorrhage. Stroke 1991;22:1519-24.
27. Kröll M, Juhler M, Lindholm J. Hyponatraemia in acute brain disease. J Intern Med 1992;232:291-7.